Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death
Background—HbA1c is the standard measure to monitor glucose control in diabetes and is a marker of future cardiovascular risk. Fructosamine and glycated albumin are markers of short-term glycemic control but their associations with cardiovascular outcomes are uncharacterized.
Methods and Results—We measured glycated albumin and fructosamine in 11,104 participants with and without diabetes in the community-based Atherosclerosis Risk in Communities (ARIC) Study in 1990-1992 (baseline). We evaluated associations of fructosamine and glycated albumin with risk of coronary heart disease, ischemic stroke, heart failure and mortality. We compared associations to those observed for HbA1c. During two decades of follow-up there were 1096 new cases of coronary heart disease, 605 of ischemic stroke, 1432 of heart failure, and 2860 deaths. Elevated baseline concentrations of fructosamine and glycated albumin were significantly associated with each of the outcomes even after adjustment for traditional cardiovascular risk factors, with especially strong associations in persons with diabetes. Associations were of similar magnitude to those observed for HbA1c and—as has been previously observed for HbA1c—the associations tended to be J-shaped, with an elevation of risk at the lowest levels of each biomarker.
Conclusions—The acceptance of new measures of hyperglycemia is partly dependent on establishing their association with long-term outcomes. We found that fructosamine and glycated albumin were associated with vascular outcomes and mortality and that these associations were similar to those observed for HbA1c.
- Received January 9, 2015.
- Revision received May 7, 2015.
- Accepted May 15, 2015.